Edition:
United Kingdom

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.50USD
14 Dec 2018
Change (% chg)

$-0.91 (-3.73%)
Prev Close
$24.41
Open
$24.09
Day's High
$24.58
Day's Low
$23.33
Volume
17,843
Avg. Vol
14,136
52-wk High
$39.67
52-wk Low
$23.04

Latest Key Developments (Source: Significant Developments)

Albireo Q3 Loss Per Share $1.17
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.17.Q3 REVENUE $237,000.Q3 REVENUE VIEW $892,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.ODEVIXIBAT SELECTED AS INTERNATIONAL NONPROPRIETARY NAME (INN) FOR A4250.A4250 GRANTED FAST TRACK AND ADDITIONAL ORPHAN DRUG DESIGNATIONS.A4250 PHASE 3 TRIAL PROGRESSING AS PLANNED, NEW NATURAL HISTORY DATA PRESENTED AT AASLD.ALBIREO PHARMA - HAD CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 OF $173.6 MILLION, COMPARED TO $53.2 MILLION AT DEC 31, 2017.ALBIREO PHARMA - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.ALBIREO PHARMA - FOR FY 2018, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE AT HIGH END OF RANGE OF $45 MILLION -$50 MILLION.  Full Article

Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Albireo posts Q3 loss per share $0.73‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​.Albireo Pharma Inc - ‍revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016​.Albireo Pharma Inc - qtrly loss per share $0.73‍​.Albireo Pharma - ‍expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018​.  Full Article

Albireo Pharma files for mixed shelf of up to $125 million‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​.  Full Article